Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Metabolic reprogramming of acute lymphoblastic leukemia cells in response to glucocorticoid treatment.

Dyczynski M, Vesterlund M, Björklund AC, Zachariadis V, Janssen J, Gallart-Ayala H, Daskalaki E, Wheelock CE, Lehtiö J, Grandér D, Tamm KP, Nilsson R.

Cell Death Dis. 2018 Aug 28;9(9):846. doi: 10.1038/s41419-018-0625-7.

2.

STAT3 differential scanning fluorimetry and differential scanning light scattering assays: Addressing a missing link in the characterization of STAT3 inhibitor interactions.

Desroses M, Busker S, Astorga-Wells J, Attarha S, Kolosenko I, Zubarev RA, Helleday T, Grandér D, Page BDG.

J Pharm Biomed Anal. 2018 Oct 25;160:80-88. doi: 10.1016/j.jpba.2018.07.018. Epub 2018 Jul 17.

PMID:
30086509
3.

Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.

Dyczynski M, Yu Y, Otrocka M, Parpal S, Braga T, Henley AB, Zazzi H, Lerner M, Wennerberg K, Viklund J, Martinsson J, Grandér D, De Milito A, Pokrovskaja Tamm K.

Cancer Lett. 2018 Oct 28;435:32-43. doi: 10.1016/j.canlet.2018.07.028. Epub 2018 Jul 25.

4.

An antisense RNA capable of modulating the expression of the tumor suppressor microRNA-34a.

Serviss JT, Andrews N, Van den Eynden J, Richter FC, Houtman M, Vesterlund M, Schwarzmueller L, Johnsson P, Larsson E, Grandér D, Pokrovskaja Tamm K.

Cell Death Dis. 2018 Jul 3;9(7):736. doi: 10.1038/s41419-018-0777-5.

5.

ClusterSignificance: a bioconductor package facilitating statistical analysis of class cluster separations in dimensionality reduced data.

Serviss JT, Gådin JR, Eriksson P, Folkersen L, Grandér D.

Bioinformatics. 2017 Oct 1;33(19):3126-3128. doi: 10.1093/bioinformatics/btx393.

PMID:
28957498
6.

The molecular dynamics of long noncoding RNA control of transcription in PTEN and its pseudogene.

Lister N, Shevchenko G, Walshe JL, Groen J, Johnsson P, Vidarsdóttir L, Grander D, Ataide SF, Morris KV.

Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):9942-9947. doi: 10.1073/pnas.1621490114. Epub 2017 Aug 28.

7.

RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.

Kolosenko I, Edsbäcker E, Björklund AC, Hamil AS, Goroshchuk O, Grandér D, Dowdy SF, Palm-Apergi C.

J Control Release. 2017 Sep 10;261:199-206. doi: 10.1016/j.jconrel.2017.07.002. Epub 2017 Jul 3.

PMID:
28684168
8.

Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells.

Liu LL, Béziat V, Oei VYS, Pfefferle A, Schaffer M, Lehmann S, Hellström-Lindberg E, Söderhäll S, Heyman M, Grandér D, Malmberg KJ.

Cancer Immunol Res. 2017 Aug;5(8):654-665. doi: 10.1158/2326-6066.CIR-16-0296. Epub 2017 Jun 21.

9.

Identification of novel small molecules that inhibit STAT3-dependent transcription and function.

Kolosenko I, Yu Y, Busker S, Dyczynski M, Liu J, Haraldsson M, Palm Apergi C, Helleday T, Tamm KP, Page BDG, Grander D.

PLoS One. 2017 Jun 21;12(6):e0178844. doi: 10.1371/journal.pone.0178844. eCollection 2017.

10.

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.

Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros LJ, Young KH, Rassidakis GZ.

Leukemia. 2017 Jul;31(7):1633-1637. doi: 10.1038/leu.2017.103. Epub 2017 Mar 27. No abstract available.

PMID:
28344319
11.

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD, Calderón-Montaño JM, Loseva O, Jemth AS, Bulli L, Axelsson H, Tesi B, Valerie NC, Höglund A, Bladh J, Wiita E, Sundin M, Uhlin M, Rassidakis G, Heyman M, Tamm KP, Warpman-Berglund U, Walfridsson J, Lehmann S, Grandér D, Lundbäck T, Kogner P, Henter JI, Helleday T, Schaller T.

Nat Med. 2017 Feb;23(2):256-263. doi: 10.1038/nm.4265. Epub 2017 Jan 9.

PMID:
28067901
12.

Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.

Lindqvist CM, Lundmark A, Nordlund J, Freyhult E, Ekman D, Carlsson Almlöf J, Raine A, Övernäs E, Abrahamsson J, Frost BM, Grandér D, Heyman M, Palle J, Forestier E, Lönnerholm G, Berglund EC, Syvänen AC.

Oncotarget. 2016 Sep 27;7(39):64071-64088. doi: 10.18632/oncotarget.11773.

13.

MicroRNA-203 Inversely Correlates with Differentiation Grade, Targets c-MYC, and Functions as a Tumor Suppressor in cSCC.

Lohcharoenkal W, Harada M, Lovén J, Meisgen F, Landén NX, Zhang L, Lapins J, Mahapatra KD, Shi H, Nissinen L, Kähäri VM, Ståhle M, Sonkoly E, Grandér D, Arsenian-Henriksson M, Pivarcsi A.

J Invest Dermatol. 2016 Dec;136(12):2485-2494. doi: 10.1016/j.jid.2016.06.630. Epub 2016 Jul 22.

14.

Tumor acidosis enhances cytotoxic effects and autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells.

Pellegrini P, Dyczynski M, Sbrana FV, Karlgren M, Buoncervello M, Hägg-Olofsson M, Ma R, Hartman J, Bajalica-Lagercrantz S, Grander D, Kharaziha P, De Milito A.

Oncotarget. 2016 Jun 14;7(24):35703-35723. doi: 10.18632/oncotarget.9601.

15.

Sorafenib-induced defective autophagy promotes cell death by necroptosis.

Kharaziha P, Chioureas D, Baltatzis G, Fonseca P, Rodriguez P, Gogvadze V, Lennartsson L, Björklund AC, Zhivotovsky B, Grandér D, Egevad L, Nilsson S, Panaretakis T.

Oncotarget. 2015 Nov 10;6(35):37066-82. doi: 10.18632/oncotarget.5797.

16.

Pseudogene-Expressed RNAs: Emerging Roles in Gene Regulation and Disease.

Grandér D, Johnsson P.

Curr Top Microbiol Immunol. 2016;394:111-26. doi: 10.1007/82_2015_442. Review.

PMID:
25982975
17.

Expression of the p53 target Wig-1 is associated with HPV status and patient survival in cervical carcinoma.

Xu LD, Muller S, Thoppe SR, Hellborg F, Kanter L, Lerner M, Zheng B, Lagercrantz SB, Grandér D, Wallin KL, Wiman KG, Larsson C, Andersson S.

PLoS One. 2014 Nov 7;9(11):e111125. doi: 10.1371/journal.pone.0111125. eCollection 2014.

18.

The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing.

Lindqvist CM, Nordlund J, Ekman D, Johansson A, Moghadam BT, Raine A, Övernäs E, Dahlberg J, Wahlberg P, Henriksson N, Abrahamsson J, Frost BM, Grandér D, Heyman M, Larsson R, Palle J, Söderhäll S, Forestier E, Lönnerholm G, Syvänen AC, Berglund EC.

Hum Mutat. 2015 Jan;36(1):118-28. doi: 10.1002/humu.22719.

19.

Cell crowding induces interferon regulatory factor 9, which confers resistance to chemotherapeutic drugs.

Kolosenko I, Fryknäs M, Forsberg S, Johnsson P, Cheon H, Holvey-Bates EG, Edsbäcker E, Pellegrini P, Rassoolzadeh H, Brnjic S, Larsson R, Stark GR, Grandér D, Linder S, Tamm KP, De Milito A.

Int J Cancer. 2015 Feb 15;136(4):E51-61. doi: 10.1002/ijc.29161. Epub 2014 Sep 4.

20.

An emerging role for long non-coding RNAs in cancer metastasis.

Serviss JT, Johnsson P, Grandér D.

Front Genet. 2014 Jul 18;5:234. doi: 10.3389/fgene.2014.00234. eCollection 2014. Review.

21.

AmotL2 disrupts apical-basal cell polarity and promotes tumour invasion.

Mojallal M, Zheng Y, Hultin S, Audebert S, van Harn T, Johnsson P, Lenander C, Fritz N, Mieth C, Corcoran M, Lembo F, Hallström M, Hartman J, Mazure NM, Weide T, Grandér D, Borg JP, Uhlén P, Holmgren L.

Nat Commun. 2014 Aug 1;5:4557. doi: 10.1038/ncomms5557.

PMID:
25080976
22.

Pseudogenes: a novel source of trans-acting antisense RNAs.

Johnsson P, Morris KV, Grandér D.

Methods Mol Biol. 2014;1167:213-26. doi: 10.1007/978-1-4939-0835-6_14. Review.

PMID:
24823780
23.

IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma.

Kolosenko I, Grander D, Tamm KP.

Curr Med Chem. 2014;21(26):3042-7. Review.

PMID:
24735367
24.

Evolutionary conservation of long non-coding RNAs; sequence, structure, function.

Johnsson P, Lipovich L, Grandér D, Morris KV.

Biochim Biophys Acta. 2014 Mar;1840(3):1063-71. doi: 10.1016/j.bbagen.2013.10.035. Epub 2013 Oct 27. Review.

25.

Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas.

Högfeldt T, Johnsson P, Grandér D, Bahnassy AA, Porwit A, Eid S, Österborg A, Zekri AR, Lundahl J, Khaled MH, Mellstedt H, Moshfegh A.

Leuk Lymphoma. 2014 May;55(5):1158-65. doi: 10.3109/10428194.2013.824077. Epub 2013 Aug 31.

PMID:
23841503
26.

CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.

Cepeda D, Ng HF, Sharifi HR, Mahmoudi S, Cerrato VS, Fredlund E, Magnusson K, Nilsson H, Malyukova A, Rantala J, Klevebring D, Viñals F, Bhaskaran N, Zakaria SM, Rahmanto AS, Grotegut S, Nielsen ML, Szigyarto CA, Sun D, Lerner M, Navani S, Widschwendter M, Uhlén M, Jirström K, Pontén F, Wohlschlegel J, Grandér D, Spruck C, Larsson LG, Sangfelt O.

EMBO Mol Med. 2013 Jul;5(7):1067-86. doi: 10.1002/emmm.201202341. Epub 2013 Jun 14.

27.

TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.

Gatt ME, Takada K, Mani M, Lerner M, Pick M, Hideshima T, Carrasco DE, Protopopov A, Ivanova E, Sangfelt O, Grandér D, Barlogie B, Shaughnessy JD Jr, Anderson KC, Carrasco DR.

Br J Haematol. 2013 Jul;162(2):210-20. doi: 10.1111/bjh.12365. Epub 2013 May 7.

28.

MicroRNA-9 regulates the expression of peroxisome proliferator-activated receptor δ in human monocytes during the inflammatory response.

Thulin P, Wei T, Werngren O, Cheung L, Fisher RM, Grandér D, Corcoran M, Ehrenborg E.

Int J Mol Med. 2013 May;31(5):1003-10. doi: 10.3892/ijmm.2013.1311. Epub 2013 Mar 20.

29.

A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells.

Johnsson P, Ackley A, Vidarsdottir L, Lui WO, Corcoran M, Grandér D, Morris KV.

Nat Struct Mol Biol. 2013 Apr;20(4):440-6. doi: 10.1038/nsmb.2516. Epub 2013 Feb 24.

30.

An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.

Lin H, Kolosenko I, Björklund AC, Protsyuk D, Österborg A, Grandér D, Tamm KP.

Exp Cell Res. 2013 Mar 10;319(5):600-11. doi: 10.1016/j.yexcr.2012.12.006. Epub 2012 Dec 13.

PMID:
23246572
31.

Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells.

Ottosson-Wadlund A, Ceder R, Preta G, Pokrovskaja K, Grafström RC, Heyman M, Söderhäll S, Grandér D, Hedenfalk I, Robertson JD, Fadeel B.

Mol Pharmacol. 2013 Jan;83(1):245-55. doi: 10.1124/mol.112.080788. Epub 2012 Oct 23.

PMID:
23093495
32.

GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia.

Holmlund T, Lindberg MJ, Grander D, Wallberg AE.

Leukemia. 2013 Mar;27(3):578-85. doi: 10.1038/leu.2012.265. Epub 2012 Sep 11.

PMID:
23044487
33.

Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.

Daneshmanesh AH, Porwit A, Hojjat-Farsangi M, Jeddi-Tehrani M, Tamm KP, Grandér D, Lehmann S, Norin S, Shokri F, Rabbani H, Mellstedt H, Österborg A.

Leuk Lymphoma. 2013 Apr;54(4):843-50. doi: 10.3109/10428194.2012.731599. Epub 2012 Oct 9.

PMID:
22988987
34.

Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.

Kharaziha P, De Raeve H, Fristedt C, Li Q, Gruber A, Johnsson P, Kokaraki G, Panzar M, Laane E, Osterborg A, Zhivotovsky B, Jernberg-Wiklund H, Grandér D, Celsing F, Björkholm M, Vanderkerken K, Panaretakis T.

Cancer Res. 2012 Oct 15;72(20):5348-62. doi: 10.1158/0008-5472.CAN-12-0658. Epub 2012 Sep 4.

35.

Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway.

Arabi A, Ullah K, Branca RM, Johansson J, Bandarra D, Haneklaus M, Fu J, Ariës I, Nilsson P, Den Boer ML, Pokrovskaja K, Grandér D, Xiao G, Rocha S, Lehtiö J, Sangfelt O.

Nat Commun. 2012;3:976. doi: 10.1038/ncomms1975.

36.

Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells.

Buentke E, Nordström A, Lin H, Björklund AC, Laane E, Harada M, Lu L, Tegnebratt T, Stone-Elander S, Heyman M, Söderhäll S, Porwit A, Ostenson CG, Shoshan M, Tamm KP, Grandér D.

Blood Cancer J. 2011 Jul;1(7):e31. doi: 10.1038/bcj.2011.27. Epub 2011 Jul 29.

37.

MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion.

Xu N, Zhang L, Meisgen F, Harada M, Heilborn J, Homey B, Grandér D, Ståhle M, Sonkoly E, Pivarcsi A.

J Biol Chem. 2012 Aug 24;287(35):29899-908. doi: 10.1074/jbc.M112.391243. Epub 2012 Jul 10.

38.

MiR-200c regulates Noxa expression and sensitivity to proteasomal inhibitors.

Lerner M, Haneklaus M, Harada M, Grandér D.

PLoS One. 2012;7(5):e36490. doi: 10.1371/journal.pone.0036490. Epub 2012 May 15.

39.

Involvement of miR17 pathway in glucocorticoid-induced cell death in pediatric acute lymphoblastic leukemia.

Harada M, Pokrovskaja-Tamm K, Söderhäll S, Heyman M, Grander D, Corcoran M.

Leuk Lymphoma. 2012 Oct;53(10):2041-50. doi: 10.3109/10428194.2012.678004. Epub 2012 May 22.

PMID:
22475310
40.

Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.

Kharaziha P, Rodriguez P, Li Q, Rundqvist H, Björklund AC, Augsten M, Ullén A, Egevad L, Wiklund P, Nilsson S, Kroemer G, Grander D, Panaretakis T.

Cell Death Dis. 2012 Jan 26;3:e262. doi: 10.1038/cddis.2012.1.

41.

MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma.

Sonkoly E, Lovén J, Xu N, Meisgen F, Wei T, Brodin P, Jaks V, Kasper M, Shimokawa T, Harada M, Heilborn J, Hedblad MA, Hippe A, Grandér D, Homey B, Zaphiropoulos PG, Arsenian-Henriksson M, Ståhle M, Pivarcsi A.

Oncogenesis. 2012 Mar 12;1:e3. doi: 10.1038/oncsis.2012.3.

42.

MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression.

Lerner M, Lundgren J, Akhoondi S, Jahn A, Ng HF, Akbari Moqadam F, Oude Vrielink JA, Agami R, Den Boer ML, Grandér D, Sangfelt O.

Cell Cycle. 2011 Jul 1;10(13):2172-83. Epub 2011 Jul 1.

PMID:
21597324
43.

Autophagy: cancer therapy's friend or foe?

Grandér D, Panaretakis T.

Future Med Chem. 2010 Feb;2(2):285-97. doi: 10.4155/fmc.09.155. Review.

PMID:
21426194
44.

Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.

Akhoondi S, Lindström L, Widschwendter M, Corcoran M, Bergh J, Spruck C, Grandér D, Sangfelt O.

Breast Cancer Res. 2010;12(6):R105. doi: 10.1186/bcr2788. Epub 2010 Dec 1.

45.

Activation of STAT1 is required for interferon-alpha-mediated cell death.

Arulampalam V, Kolosenko I, Hjortsberg L, Björklund AC, Grandér D, Tamm KP.

Exp Cell Res. 2011 Jan 1;317(1):9-19. doi: 10.1016/j.yexcr.2010.10.002. Epub 2010 Oct 16.

PMID:
20937272
46.

Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro.

Ullén A, Farnebo M, Thyrell L, Mahmoudi S, Kharaziha P, Lennartsson L, Grandér D, Panaretakis T, Nilsson S.

Int J Oncol. 2010 Jul;37(1):15-20.

PMID:
20514392
47.

Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies.

Grandér D, Kharaziha P, Laane E, Pokrovskaja K, Panaretakis T.

Autophagy. 2009 Nov;5(8):1198-200. Epub 2009 Nov 18.

PMID:
19855186
48.

The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element.

Vilborg A, Glahder JA, Wilhelm MT, Bersani C, Corcoran M, Mahmoudi S, Rosenstierne M, Grandér D, Farnebo M, Norrild B, Wiman KG.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15756-61. doi: 10.1073/pnas.0900862106. Epub 2009 Sep 1.

49.

Characterisation of hairy cell leukaemia by tiling resolution array-based comparative genome hybridisation: a series of 13 cases and review of the literature.

Nordgren A, Corcoran M, Sääf A, Bremer A, Kluin-Nelemans HC, Schoumans J, Grandér D.

Eur J Haematol. 2010 Jan 1;84(1):17-25. doi: 10.1111/j.1600-0609.2009.01334.x. Review.

PMID:
19682064
50.

DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1.

Lerner M, Harada M, Lovén J, Castro J, Davis Z, Oscier D, Henriksson M, Sangfelt O, Grandér D, Corcoran MM.

Exp Cell Res. 2009 Oct 15;315(17):2941-52. doi: 10.1016/j.yexcr.2009.07.001. Epub 2009 Jul 8.

PMID:
19591824

Supplemental Content

Loading ...
Support Center